Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.

Leukemia & Lymphoma
Susanne Bram EdnerssonPer-Ola Andersson

Abstract

The complexity of the activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) subtype is probably not only explained by genetic alterations and methods to measure global protein expression could bring new knowledge regarding the pathophysiology. We used quantitative proteomics to analyze the global protein expression of formalin-fixed paraffin-embedded (FFPE) tumor tissues from 202 DLBCL patients. We identified 6430 proteins and 498 were significantly regulated between the germinal center B-cell like (GCB) and non-GCB groups. A number of proteins previously not described to be upregulated in non-GCB or ABC DLBCL was found, e.g. CD64, CD85A, guanylate-binding protein 1 (GBP1), interferon-induced proteins with tetratricopeptide repeat (IFIT)2, and mixed lineage kinase domain-like protein (MLKL) and immunohistochemical staining showed higher expression of GBP1 and MLKL. A cluster analysis revealed that the most prominent cluster contained proteins involved in the tumor microenvironment and regulation of the immune system. Our data suggest that the therapeutic focus should be expanded toward the tumor microenvironment in non-GCB/ABC subtype patients.

References

Jul 20, 2005·Cancer Chemotherapy and Pharmacology·Zhenfeng DuanMichael V Seiden
Jan 4, 2012·Histopathology·Naoki WadaUNKNOWN Osaka Lymphoma Study Group
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathalie A JohnsonRandy D Gascoyne
Mar 31, 2015·Seminars in Cancer Biology·Dass S VinayByoung S Kwon
Aug 28, 2015·Molecular & Cellular Proteomics : MCP·Sally J DeebMatthias Mann
May 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisTimothy Bullock
Jun 24, 2017·Cancer Immunology, Immunotherapy : CII·William van der TouwShu-Hsia Chen
Apr 5, 2018·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Anna KwiecińskaSerhiy Souchelnytskyi
Apr 12, 2018·The New England Journal of Medicine·Roland SchmitzLouis M Staudt
May 17, 2018·British Journal of Haematology·Susanne Bram EdnerssonPer-Ola Andersson
Jun 27, 2018·Cell Research·Delong JiaoZheng-Gang Liu
Nov 1, 2018·The New England Journal of Medicine·Ranjana AdvaniSonali M Smith
Feb 23, 2019·Proteomics. Clinical Applications·Sophia DollMatthias Mann
Mar 23, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesUNKNOWN PHOENIX investigators
Apr 26, 2019·International Journal of Cancer. Journal International Du Cancer·János T Fekete, Balázs Győrffy
May 28, 2019·Molecular Cancer·Yitao GongChen Liu
Nov 23, 2019·Journal for Immunotherapy of Cancer·Eleanor M ScottMargaret R Duffy
Jan 11, 2020·Frontiers in Molecular Biosciences·Vijaya Kumar PiduguTe-Chang Lee
Jan 15, 2020·Analytical Cellular Pathology (Amsterdam)·Alexandra Ioana CioroianuFlorica Staniceanu
Mar 3, 2020·Frontiers in Immunology·Alexander T HonkalaSanjay V Malhotra
Mar 11, 2020·ESMO Open·Angelika M Starzer, Anna S Berghoff
May 15, 2020·Blood·Ryan D Morin, David W Scott

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.